Pangaea Oncology S.A. (PANG) — Cash Flow-to-Debt Ratio
Pangaea Oncology S.A. (PANG) has a Cash Flow-to-Debt Ratio of -0.15x as of June 2025, meaning its operating cash flow of €-1.26 Million could theoretically repay 0% of its total liabilities (€8.43 Million) in one year. See Pangaea Oncology S.A. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Pangaea Oncology S.A. Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Pangaea Oncology S.A. across 12 annual periods. Also explore net asset momentum of Pangaea Oncology S.A. to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Pangaea Oncology S.A. (2013–2024)
Year-by-year debt coverage analysis for Pangaea Oncology S.A.. For market capitalisation and broader financial context, see Pangaea Oncology S.A. (PANG) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.48x | €-4.57 Million | €9.57 Million | ▼ -99.5% |
| 2023 | -0.24x | €-2.40 Million | €10.03 Million | ▲ +65.5% |
| 2022 | -0.69x | €-3.68 Million | €5.30 Million | ▼ -87.6% |
| 2021 | -0.37x | €-2.50 Million | €6.76 Million | ▼ -66.1% |
| 2020 | -0.22x | €-1.92 Million | €8.61 Million | ▲ +20.5% |
| 2019 | -0.28x | €-2.40 Million | €8.56 Million | ▼ -51.7% |
| 2018 | -0.18x | €-2.17 Million | €11.74 Million | ▲ +60.4% |
| 2017 | -0.47x | €-6.48 Million | €13.91 Million | ▼ -211.4% |
| 2016 | -0.15x | €-1.78 Million | €11.89 Million | ▲ +35.5% |
| 2015 | -0.23x | €-2.31 Million | €9.95 Million | ▲ +16.2% |
| 2014 | -0.28x | €-1.89 Million | €6.83 Million | ▼ -97.8% |
| 2013 | -0.14x | €-659.69K | €4.71 Million | — |